BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9570426)

  • 21. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
    Alpert JS
    Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
    [No Abstract]   [Full Text] [Related]  

  • 23. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
    Charlon V; Kobrin I
    Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
    Ruzyllo W; Tendera M; Ford I; Fox KM
    Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open comparative study to assess the efficacy and safety of two calcium antagonists: amlodipine and diltiazem in the treatment of symptomatic myocardial ischemia.
    Canale C; Terrachini V; Masperone MA; Caponnetto S
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S57-60. PubMed ID: 16296712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
    Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN
    Clin Ther; 1997; 19(6):1368-78. PubMed ID: 9444446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
    Bittar N
    Clin Ther; 1997; 19(5):954-62. PubMed ID: 9385483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.
    Lee DS; Goodman S; Dean DM; Lenis J; Ma P; Gervais PB; Langer A;
    Am Heart J; 2002 Jul; 144(1):60-7. PubMed ID: 12094189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mibefradil: a selective T-type calcium antagonist.
    Massie BM
    Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: comparison with amlodipine.
    Roux S; Bühler M; Clozel JP
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):132-9. PubMed ID: 8656647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind comparison of the efficacy and tolerability of once-daily modified-release diltiazem capsules with once-daily amlodipine tablets in patients with stable angina.
    Chugh SK; Digpal K; Hutchinson T; McDonald CJ; Miller AJ; Lahiri A
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):356-64. PubMed ID: 11486240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
    Portegies MC; Schmitt R; Kraaij CJ; Braat SH; Gassner A; Hagemeijer F; Pozenel H; Prager G; Viersma JW; van der Wall EE
    J Cardiovasc Pharmacol; 1991 Nov; 18(5):746-51. PubMed ID: 1723772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
    Viskoper RJ; Bernink PJ; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I
    J Hum Hypertens; 1997 Jun; 11(6):387-93. PubMed ID: 9249234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of metoprolol and amlodipine on myocardial total ischaemic burden in patients with stable angina pectoris.
    Klein G; Pfafferott C; Beil S; Gehring J; Niemelä M; Kendall MJ
    J Clin Pharm Ther; 1997; 22(5-6):371-8. PubMed ID: 19160722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris.
    Bernink PJ; de Weerd P; ten CF; Remme WJ; Barth J; Enthoven R; Haagen FD; Holwerda NJ; Klomps HC
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S53-6. PubMed ID: 16296711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.